Product Licence-Parallel Import Post - September 2024

View as a webpage / Share

MHRA banner

PLPIPost - September 2024


In this issue

Pharmacovigilance (PV) for PLPI licences – a reminder

Wholesalers & manufacturers guidance following agreement of the Windsor Framework

PLPI Information Update

Contacting assessors/ RIS / Customer services - a reminder

Admin team zone

Monthly statistics


Pharmacovigilance (PV) for PLPI licences – a reminder

As part of the PLPI licence grant conditions, when the cross-reference UK licence has been cancelled for non-safety related reasons (rather than undergoing a change of ownership), the PI licence holder is required to take on responsibility for pharmacovigilance of the imported product to continue marketing the product in the UK.

A transition period of 6 months will be allowed for companies to consider whether to cancel their licence or put in place PV requirements.

PV requirements comprise of two main aspects:

1. Management of ADR reports

The PLPI holder must:

  • Collate and maintain records relating to suspected adverse drug reactions (ADRs) reported to them.
  • Make the above records available for inspection as required.
  • Report serious ADRs to the MHRA.

In addition to the above, all ADRs reported to the PI holder must also be reported to the MHRA via the Yellow Card scheme.

Further information on submitting ADRs can be found on the MHRA website and the Yellow Card reporting site.

2. Maintenance of the patient information

The PI licence holder must ensure that the leaflet included in the medicine pack contains up to date information on the safe and effective use of the medicine. Initially, the PI leaflet should comply with the latest revision of the cross-referred UK product leaflet. The PI licence holder must then carry out monthly checks to monitor all appropriate information sources (e.g. PRAC recommendations, safety referrals, PSURs, CMDh agendas and minutes etc.) and update the leaflet, as necessary.

Records of monitoring activity must be maintained and updates to labels may also be required.

Additional measures may be required for some products, for example additional risk minimisation measures (aRMMs) and Periodic Safety Update Reports (PSURs). The need for these will be determined on a case-by-case basis.

PI licence holders must develop their own internal processes and procedures to fulfil these responsibilities and you must also ensure that suitably qualified PV and regulatory staff are available to operate the processes.

The effectiveness of the PV systems will be checked during inspections and may be the subject of a separate PV inspection visit.

For further information on PV requirements, please refer to the PLPI Posts dated February 2020 and February 2021.

We may occasionally include a current list of cancelled UK cross-reference licences, however the responsibility for checking the status of the UK cross-reference licence is with the PI licence holder. These checks should be part of your monthly licence checks.

Below is a current list of cancelled UK cross-reference licences. Please ensure that if any of your PI licences are cross-referred to any of these cancelled UK licences that you undertake additional PV responsibilities or you cancel your licence.

Product Name

UK PL/PLGB No

Active

Cancellation date

Actonel 5mg Film-coated Tablets

PL 20075/1067

risedronate sodium

18/11/2022

Actos 15 mg tablets

PLGB 45043/0086

pioglitazone hydrochloride

11/01/2023

Actos 30 mg tablets

PLGB 45043/0087

pioglitazone hydrochloride

11/01/2023

Actos 45 mg tablets

PLGB 45043/0088

pioglitazone hydrochloride

11/01/2023

Acupan Tablets

PL 46302/0091

nefopam hydrochloride

20/04/2022

Adalat LA 60mg tablets

PL 00010/0175

nifedipine

26/11/2020

Adalat Retard 20mg tablets

PL 00010/0078

nifedipine

01/10/2019

Anafranil 75mg

PL 00101/0436

clomipramine hydrochloride

24/07/2018

Antepsin 1g/5ml oral suspension

PL 12185/0010

sucralfate

20/09/2019

Aprovel 75mg Tablets

PLGB 04425/0790

irbesartan

11/05/2021

Artelac 0.32% w/v eye drops single dose unit

PL 03468/0033

hypromellose

23/07/2024

Bromocriptine 2.5 mg Tablets

PL 00289/1395

bromocriptine mesylate

09/12/2019

Celectol 400 Tablets  

PL 45043/0028

celiprolol hydrochloride

13/10/2023

CoAprovel 300mg/25mg film-coated Tablets

PLGB 04425/0793

irbesartan, hydrochlorothiazide

09/08/2023

Co-danthramer 25mg/200mg per 5ml oral suspension

PL 04917/0025

dantron, poloxamer 188

29/05/2024

Danol 200mg Capsules

PL 04425/0195

danazol

02/12/2022

Desmopressin Teva 0.1mg tabs

PL 00289/1010

desmopressin

28/12/2017

Detrunorm 15mg Coated Tablets  

PL 20072/0015

propiverine hydrochloride

25/03/2022

Flagyl S 200mg/5ml oral suspension

PL 04425/0747

metronidazole benzoate

18/01/2022

Flixotide 0.5mg/2ml Nebules

PL 10949/0297

fluticasone propionate

07/05/2024

Flixotide 2mg/2ml Nebules

PL 10949/0298

fluticasone propionate

06/12/2023

Foradil 12mcg Capsules

Pl 00101/0464

formoterol fumarate

18/03/2023

Frumil LS 20 mg/2.5 mg Tablets

PL 04425/0574

furosemide, amiloride hydrochloride

08/01/2023

Haldol 10mg

PL 00242/0039R

haloperidol

20/10/2016

Haldol 5mg

PL 00242/0031R

haloperidol

20/10/2016

Haldol injection

PL 00242/0036R

haloperidol

21/05/2018

Hygroton 50mg Tablets

PL 16853/0007

chlortalidone

22/04/2020

Hygroton 50mg Tablets

PL 42757/0006

chlortalidone

26/05/2020

Hypovase 1mg Tablets

PL 00057/0106R

prazosin hydrochloride

23/06/2023

Jevtana 60mg concentrate and solvent for solution for infusion

PLGB 04425/0825

cabazitaxel

04/08/2023

Lescol XL 80mg Prolonged Release Tablets

PL 23860/0015

fluvastatin sodium

20/02/2023

Levitra 20mg film-coated Tablets

PLGB 00010/0699

vardenafil hydrochloride trihydrate

26/06/2023

Lyrinel XL 5mg prolonged-release tablets

PL 00242/0385

oxybutynin hydrochloride

15/09/2022

Lyxumia 20 mcg solution for injection

PLGB 04425/0832

lixisenatide

03/01/2024

Megace 160mg Tablets

PL 03468/0089

megestrol acetate

15/01/2024

Metoject 50 mg/ml solution for injection

PL 11587/0046

methotrexate

21/06/2021

Nalacrom 100mg Capsules

PL 04425/0370

sodium cromoglicate

20/06/2023

Ofloxacin Teva 400mg tablets

PL 14776/0055

ofloxacin

02/12/2019

Rasilez 150 mg film-coated tablets

PLGB 48724/0001

aliskiren hemifumarate

01/08/2024

Rasilez 300 mg film-coated tablets

PLGB 48724/0002

aliskiren hemifumarate

01/08/2024

Restandol Testocaps 40mg capsules

PL 00025/0595

testosterone undecanote

06/01/2021

Rhinocort Aqua 64 micrograms Nasal Spray

PL 15513/0403

budesonide

28/06/2021

Rinatec 21 micrograms per metered dose, Nasal Spray Solution

PL 53886/0059

ipratropium bromide

10/05/2024

Risperdal 0.5mg Tablets

PL 00242/0347

risperidone

19/01/2024

Risperdal 1mg Tablets

PL 00242/0186

risperidone

19/01/2024

Risperdal 1mg/ml oral solution

PL 00242/0199

risperidone

19/01/2024

Risperdal 2mg Tablets

PL 00242/0187

risperidone

19/01/2024

Risperdal 3mg Tablets

PL 00242/0188

risperidone

19/01/2024

Rivotril 0.5mg

PL 00031/0076R

clonazepam

31/08/2014

Rivotril 2mg

PL 00031/0077R

clonazepam

31/08/2014

Rizatriptan 10mg orodispersible tablets

PL 04569/1149

rizatriptan

29/12/2023

Sectral 400mg Tablets

PL 45043/0061

acebutolol

09/03/2023

Seroxat 20mg/10ml Oral Suspension

PL 10592/0092

paroxetine

01/07/2024

Tesavel 50mg film-coated tablets

PLGB 53095/0076

sitagliptin phosphate monohydrate

20/12/2023

Transiderm-Nitro 5

PL 00101/0464

nitroglycerin

13/10/2023

Transiderm-Nitro10

PL 00101/0465

nitroglycerin

13/10/2023

Triapin 5mg/5mg prolonged release tablets

PL 04425/0320

felodipine, ramipril

21/03/2022

Voltarol SR 75mg

PL 00101/0471

diclofenac sodium

11/12/2017

Xelevia 100mg film-coated tablets

PLGB 53095/0079

sitagliptin phosphate monohydrate

20/12/2023

Xelevia 25mg film-coated tablets

PLGB 53095/0080

sitagliptin phosphate monohydrate

20/12/2023

Xelevia 50mg film-coated tablets

PLGB 53095/0081

sitagliptin phosphate monohydrate

20/12/2023

Xtandi 40mg Capsules

PLGB 00166/0422

enzalutamide

10/04/2024

Zarontin 250mg/5ml Syrup

PL 41871/0016

ethosuximide

11/05/2017

Zofran Melt 4mg

PL 00101/0983

ondansetron hydrochloride

11/07/2023

Zofran Melt 8mg

PL 00101/0984

ondansetron hydrochloride

11/07/2023

Zyprexa 10mg Injection

PLGB 14895/0289

olanzapine

23/01/2024


Wholesalers & manufacturers guidance following agreement of the Windsor Framework

A new Windsor framework guidance has been published for wholesalers and manufacturers. This guidance is designed to support manufacturers and wholesale dealers authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and the associated Qualified Persons (QPs), Responsible Persons (RPs) and Responsible Persons for Import (RPis) in order to implement the arrangements of the Windsor Framework for human medicines.


PLPI Information Update


Contacting assessors/ RIS / Customer services – a reminder

Assessors are busy working on your applications and should be contacted only if absolutely necessary.

If you wish to find out the status of your application (initials and/or variations) or you are requesting approved documentation for your granted licence such as grant letters, labelling documents or leaflets or any other enquiry relating to product licences and any other regulatory activity, please contact RIS by e-mail: RIS.NA@mhra.gov.uk or by telephone on 020 3080 7400.

To obtain the current Patient Information Leaflet (PIL) or Summary of Product Characteristics (SmPC) document, please search MHRA Products website.

For all other general enquiries, contact Customer Services by email: info@mhra.gov.uk or call 020 3080 6000.


Admin team zone


The PLPI Admin team is responsible for all administrative work for a licence - post submission validation and post application assessment. This consists of processing submitted samples, requesting product information from EU regulatory bodies, and preparing grant documentations.

For any admin related queries, please email plpi.admin@mhra.gov.uk


Monthly statistics


Every month a series of reports from the Sentinel database are run to monitor various aspects of Parallel Import Licence granting performance. Each month we will include the current statistics for some key parameters in The PLPI Post so that you can see how we are doing. Please let us know if there is something you would like included.

Measure

July   2024  

 

August 2024 

 

September  2024

Initial Parallel Import Applications received

104 55 53

Initial Parallel Import Licences granted

85 72 120

Initial Parallel Import Applications determined

86 75 123

Minimum time to grant (months)

1.4 7.2 1.8

Median time to grant (months)

10.4 10.8 10.8

Time to start assessment (months)

10.7 9.7 9.3
       

Variations received

489 1169 440

Variations granted

1182 1489 1552

Time to grant leaflets (months)

4.2 3.0 3.6

Time to grant pharmaceutical (months)

4.0 4.5 3.4

Time to grant admin (months)

1.4 1.6 0.3

 


For any PLPI related queries contact: RIS.NA@mhra.gov.uk

Contact address: PLPI Unit / Healthcare Quality and Access, MHRA, 10 South Colonnade, Canary Wharf, London, E14 4PU

If you wish to unsubscribe to these emails, please reply to RIS.NA@mhra.gov.uk with ‘Unsubscribe’ in the subject line.

View and download the full PDF newsletter

MHRA TwitterMHRA FacebookMHRA LinkedInMHRA YouTubeMHRA Inspectorate blog